TMCI Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
48.3M
+6.3%
45.4M
-3.9%
47.2M
-24.5%
62.5M
+24.5%
50.2M
Cost of Revenue
9.9M
+1.4%
9.8M
-0.2%
9.8M
-19.2%
12.1M
+15.3%
10.5M
Gross Profit
38.4M
+7.7%
35.6M
-4.8%
37.4M
-25.8%
50.4M
+26.9%
39.7M
Operating Expenses
49.7M
-1.3%
50.4M
-7.7%
54.6M
-3.1%
56.3M
+1.9%
55.3M
R&D
4.5M
+2.7%
4.4M
-5.3%
4.6M
+1.8%
4.5M
-2.9%
4.7M
SG&A
45.4M
-1.7%
46.2M
-7.5%
50.0M
-3.5%
51.8M
+2.1%
50.7M
Operating Income
-11369000
+23.0%
-14756000
+14.0%
-17167000
-189.9%
-5922000
+62.0%
-15584000
EBITDA
-9337000
+27.4%
-12868000
+20.9%
-16268000
-422.4%
-3114000
+75.7%
-12806000
Net Income
-12622000
+20.5%
-15873000
+11.6%
-17961000
-91.2%
-9394000
+42.2%
-16255000
EPS (Basic)
$-0.19
+20.8%
$-0.24
+14.3%
$-0.28
-86.7%
$-0.15
+42.3%
$-0.26
EPS (Diluted)
$-0.19
+20.8%
$-0.24
+14.3%
$-0.28
-86.7%
$-0.15
+42.3%
$-0.26
Shares (Diluted)
65.5M
+0.6%
65.0M
+0.7%
64.6M
+1.1%
63.9M
+0.6%
63.5M
Treace Medical Concepts (TMCI) — Financials